BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen WX, Li GX, Hu ZN, Zhu P, Zhang BX, Ding ZY. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review. Medicine (Baltimore) 2019;98:e17832. [PMID: 31702638 DOI: 10.1097/MD.0000000000017832] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Xie P, Guo L, Zhang B, Xu Y, Song Q, Shi H, Ye Q, Li H, Xiao Y. Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review. Front Oncol 2022;12:911202. [DOI: 10.3389/fonc.2022.911202] [Reference Citation Analysis]
2 Shi C, Li Y, Yang C, Qiao L, Tang L, Zheng Y, Chen X, Qian Y, Yang J, Wu D, Xie F. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China. Front Immunol 2022;13:946861. [DOI: 10.3389/fimmu.2022.946861] [Reference Citation Analysis]
3 Zheng Z, Wang J, Li W, Wu T, Chen M, Zhou Z. Anti-programmed Cell Death Protein-1 Therapy in Intrahepatic Cholangiocarcinoma Induced Type 1 Diabetes: A Case Report and Literature Review. Front Public Health 2022;10:917679. [DOI: 10.3389/fpubh.2022.917679] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ning Z, Zhao Y, Yan X, Hua Y, Meng Z. Flower-like Composite Material Delivery of Co-Packaged Lenvatinib and Bufalin Prevents the Migration and Invasion of Cholangiocarcinoma. Nanomaterials (Basel) 2022;12:2048. [PMID: 35745387 DOI: 10.3390/nano12122048] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Le TMD, Yoon AR, Thambi T, Yun CO. Polymeric Systems for Cancer Immunotherapy: A Review. Front Immunol 2022;13:826876. [PMID: 35273607 DOI: 10.3389/fimmu.2022.826876] [Reference Citation Analysis]
6 Li Q, Cao M, Yuan G, Cheng X, Zang M, Chen M, Hu X, Huang J, Li R, Guo Y, Ruan J, Chen J. Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study. Front Oncol 2022;12:809709. [PMID: 35280760 DOI: 10.3389/fonc.2022.809709] [Reference Citation Analysis]
7 Liu C, Wang M, Xu C, Li B, Chen J, Chen J, Wang Z. Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation. J Immunol Res 2021;2021:8970173. [PMID: 34877360 DOI: 10.1155/2021/8970173] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
8 Zheng Y, Li Y, Feng J, Li J, Ji J, Wu L, Yu Q, Dai W, Wu J, Zhou Y, Guo C. Cellular based immunotherapy for primary liver cancer. J Exp Clin Cancer Res 2021;40:250. [PMID: 34372912 DOI: 10.1186/s13046-021-02030-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Gao Y, Zhou R, Huang JF, Hu B, Cheng JW, Huang XW, Wang PX, Peng HX, Guo W, Zhou J, Fan J, Yang XR. Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. Front Oncol 2021;11:704042. [PMID: 34327143 DOI: 10.3389/fonc.2021.704042] [Reference Citation Analysis]
10 Yao W, Gong W. Immunotherapy in cholangiocarcinoma: From concept to clinical trials. Surgery in Practice and Science 2021;5:100028. [DOI: 10.1016/j.sipas.2021.100028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Fiste O, Ntanasis-Stathopoulos I, Gavriatopoulou M, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines (Basel) 2021;9:422. [PMID: 33922362 DOI: 10.3390/vaccines9050422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhao J, Chen Y, Wang J, Wang J, Wang Y, Chai S, Zhang Y, Chen X, Zhang W. Preoperative risk grade predicts the long-term prognosis of intrahepatic cholangiocarcinoma: a retrospective cohort analysis. BMC Surg 2021;21:113. [PMID: 33676467 DOI: 10.1186/s12893-020-00954-x] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
13 Shen T, Zheng S, Geng L, Liu Z, Xu J, Lin B, Qian J, Zheng S. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review. Technol Cancer Res Treat 2020;19:1533033820979703. [PMID: 33308041 DOI: 10.1177/1533033820979703] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Su X, Liu J, Zhang H, Gu Q, Zhou X, Ji M, Yao D. Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer. Onco Targets Ther 2020;13:11183-92. [PMID: 33173310 DOI: 10.2147/OTT.S278349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Zhang W, Shi J, Wang Y, Zhou H, Zhang Z, Han Z, Li G, Yang B, Cao G, Ke Y, Zhang T, Song T, QiangLi. Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers. Cancer Immunol Immunother 2021;70:1001-14. [PMID: 33095329 DOI: 10.1007/s00262-020-02745-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
16 Guo X, Shen W. Latest evidence on immunotherapy for cholangiocarcinoma.Oncol Lett. 2020;20:381. [PMID: 33154779 DOI: 10.3892/ol.2020.12244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
17 Xu SF, Guo Y, Zhang X, Zhu XD, Fan N, Zhang ZL, Ren GB, Rao W, Zang YJ. Somatic Mutation Profiling of Intrahepatic Cholangiocarcinoma: Comparison between Primary and Metastasis Tumor Tissues. J Oncol 2020;2020:5675020. [PMID: 33014052 DOI: 10.1155/2020/5675020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Malenica I, Donadon M, Lleo A. Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine. Cancers (Basel) 2020;12:E2190. [PMID: 32781527 DOI: 10.3390/cancers12082190] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
19 Lin J, Yang X, Long J, Zhao S, Mao J, Wang D, Bai Y, Bian J, Zhang L, Yang X, Wang A, Xie F, Shi W, Yang H, Pan J, Hu K, Guan M, Zhao L, Huo L, Mao Y, Sang X, Wang K, Zhao H. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr 2020;9:414-24. [PMID: 32832493 DOI: 10.21037/hbsn-20-338] [Cited by in Crossref: 19] [Cited by in F6Publishing: 41] [Article Influence: 9.5] [Reference Citation Analysis]
20 Xiong F, Gong J, Wang Q. Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report. Onco Targets Ther 2020;13:6385-91. [PMID: 32753881 DOI: 10.2147/OTT.S250454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
21 Leoni S, Sansone V, Lorenzo S, Ielasi L, Tovoli F, Renzulli M, Golfieri R, Spinelli D, Piscaglia F. Treatment of Combined Hepatocellular and Cholangiocarcinoma. Cancers (Basel) 2020;12:E794. [PMID: 32224916 DOI: 10.3390/cancers12040794] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]